{
    "clinical_study": {
        "@rank": "8086", 
        "arm_group": {
            "arm_group_label": "Mexiletine", 
            "arm_group_type": "Experimental", 
            "description": "6-day treatment period during which the medication will be taken orally with an initial dose of: 200 mg every 8 hours for 3 doses on day 3, increasing to 300 mg every 8 hours on days 4 and 5 (6 doses), and increasing further to 400 mg every 8 hours on days 6-8 if no telemetry changes and no dose limiting side effects"
        }, 
        "brief_summary": {
            "textblock": "To understand if Mexiletine will restores normal colonic motility in a patient with\n      irritable bowel syndrome - constipation (IBS-C) and a genetic mutation in SCN5A."
        }, 
        "brief_title": "Effects of Mexiletine on Colonic Transit in a Patient With Irritable Bowel Syndrome - Constipation (IBS-C)", 
        "completion_date": {
            "#text": "November 2012", 
            "@type": "Actual"
        }, 
        "condition": "IBS", 
        "condition_browse": {
            "mesh_term": "Irritable Bowel Syndrome"
        }, 
        "detailed_description": {
            "textblock": "To understand if Mexiletine will restore normal colonic motility in a patient with a\n      missense mutation in SCN5A, which encodes a voltage-sensitive sodium channel NaV1.5 as it is\n      known to rescue certain expression defects of NaV1.5 in vitro."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Established IBS diagnosis with a known A997T mutation in NaV1.5T\n\n        Exclusion Criteria:\n\n          -  Normal 48-hour baseline transit study\n\n          -  Current use of mexiletine\n\n          -  Inability to stay in Rochester for 9 days for testing\n\n          -  Known allergy to mexiletine\n\n          -  Inability to complete daily diary\n\n          -  Taking a medication known to affect myotonia, had a coexisting  neuromuscular\n             disease, or had another serious medical illness including second- or third-degree\n             heart block, atrial flutter, atrial fibrillation, ventricular arrhythmia, history of\n             cardiac arrhythmia requiring medication, congestive heart failure, symptomatic\n             cardiomyopathy, or symptomatic coronary artery disease\n\n          -  Inability to withdraw medications known to interact with mexiletine. Patient is\n             currently not on any of these medications"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "60 Years"
        }, 
        "enrollment": {
            "#text": "1", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 18, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01717404", 
            "org_study_id": "12-006842"
        }, 
        "intervention": {
            "arm_group_label": "Mexiletine", 
            "description": "6-day treatment period during which the medication will be taken orally with an initial dose of: 200 mg every 8 hours for 3 doses on day 3, increasing to 300 mg every 8 hours on days 4 and 5 (6 doses), and increasing further to 400 mg every 8 hours on days 6-8 if no telemetry changes and no dose limiting side effects", 
            "intervention_name": "Mexiletine", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Mexiletine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "IBS", 
        "lastchanged_date": "September 30, 2013", 
        "number_of_arms": "1", 
        "official_title": "Effects of Mexiletine on Colonic Transit in a Patient With a Known SCN5A A997T Mutation", 
        "overall_official": {
            "affiliation": "Mayo Clinic", 
            "last_name": "Yuri A Saito Loftus, MD, MPH", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Colon transit will be measured using validated scintigraphy methods conducted in our Clinical Research Unit (CRU).[17, 18] The participant will ingest a Tc-99m labeled sulfur colloid in egg to be used as a stomach marker and ln-111 chloride bound to activated charcoal enclosed in a methacrylate-coated capsule to measure colonic transit.", 
            "measure": "change in the 48 hour Colon Transit", 
            "safety_issue": "Yes", 
            "time_frame": "Baseline to 10 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01717404"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Mayo Clinic", 
            "investigator_full_name": "Yuri A. Saito Loftus", 
            "investigator_title": "PI", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Mayo Clinic", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mayo Clinic", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}